Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress

Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

JD Sports up 3% after hikes returns after 'resilient' performance in tough year - UPDATE

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Uber shares surge after strong first-quarter results, bullish guidance

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Microsoft eyes AI execution, Azure growth, Copilot adoption in key Q3 earnings test

Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma to present new Teverelix data at upcoming endocrinology meeting

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline

Medicus Pharma gives Teverelix Phase 2 FDA update – ICYMI

Medicus Pharma gives Teverelix Phase 2 FDA update – ICYMI

Nasdaq leads Wall Street higher in the face of Iran tensions and oil volatility

Boot Barn upgraded by Jefferies analysts on valuation reset

Carvana rating shifted to Neutral but BofA sees long-term potential

Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients

Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA

Medicus Pharma SkinJect Phase 2 study data endorsed by independent expert - ICYMI

Medicus Pharma SkinJect Phase 2 study data endorsed by independent expert - ICYMI

Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Medicus Pharma highlights independent support for Phase 2 SkinJect results

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Up 290.7% in March

Nasdaq tumbles on tech sell-off as oil surges, Trump says Iran 'better get serious'

Medicus Pharma advances SkinJect, Teverelix programs, eyes catalyst-rich 2026

Wave Life Sciences shares plummet on weight loss therapy update

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Medicus Pharma CEO discusses promising Phase 2 SkinJect results - ICYMI

Medicus Pharma CEO discusses promising Phase 2 SkinJect results - ICYMI

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

GSK sells rights to rare liver disease drug for up to $690m